clinical trial · NCT03602261
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Secondary Hyperparathyroidism Due to Renal CausesChronic Kidney DiseasesVitamin D DeficiencyStage 5 Chronic Kidney DiseaseCalcifediol Oral CapsulePlacebo oral capsule
brief summary
Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
started
Jul 9, 2018
primary completion
Feb 24, 2021
completion
Feb 24, 2021
last updated
Apr 3, 2026
detailed description
A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 (calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism (SHPT) in Subjects with Vitamin D Insufficiency (VDI) and Chronic Kidney Disease Requiring Regular Hemodialysis.
official title
A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol